» Articles » PMID: 36683705

Kinetics of the Serological Response Up to One Year After Tularemia

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Serological analysis is the predominant method used to diagnose tularemia, a zoonotic disease caused by the highly virulent bacterium . We determined -specific IgM and IgG antibody titers by an LPS-based ELISA assay on five occasions one to twelve months after onset of ulceroglandular tularemia in 19 individuals. Peak IgM antibody titers were observed at the one-month time point and peak IgG antibody titers at the two-month time point. Both IgG and IgM antibody levels declined linearly thereafter with rather similar kinetics. Compared to the average one-month antibody titers, average IgG titers were not significantly lower before the 12-month time point and IgM titers before the 4-month time point. All, but one average titer, were significantly increased compared to the cut-off of the assay. Average IgG and IgM titers were significantly lower for the group = 69 years old compared to the group < 69 years. Collectively, the data demonstrate a persistence of -specific IgM and IgG antibody titers for at least 12 months after ulceroglandular tularemia. Thus, low, but significantly elevated -specific antibody titers are of limited diagnostic value since they are not indicative of ongoing tularemia.

Citing Articles

specific antibody levels in sera from Swedish patients with suspected tularemia during a 13-year period.

Lindgren H, Liu X, Sjostedt A Front Cell Infect Microbiol. 2024; 14:1381776.

PMID: 38628552 PMC: 11018962. DOI: 10.3389/fcimb.2024.1381776.


Targeting Tularemia: Clinical, Laboratory, and Treatment Outcomes From an 11-year Retrospective Observational Cohort in Northern Sweden.

Plymoth M, Lundqvist R, Nystedt A, Sjostedt A, Gustafsson T Clin Infect Dis. 2024; 78(5):1222-1231.

PMID: 38393822 PMC: 11093680. DOI: 10.1093/cid/ciae098.

References
1.
Eneslatt K, Rietz C, Ryden P, Stoven S, House R, Wolfraim L . Persistence of cell-mediated immunity three decades after vaccination with the live vaccine strain of Francisella tularensis. Eur J Immunol. 2011; 41(4):974-80. PMC: 3516913. DOI: 10.1002/eji.201040923. View

2.
Bevanger L, Maeland J, Kvan A . Comparative analysis of antibodies to Francisella tularensis antigens during the acute phase of tularemia and eight years later. Clin Diagn Lab Immunol. 1994; 1(2):238-40. PMC: 368235. DOI: 10.1128/cdli.1.2.238-240.1994. View

3.
Crooke S, Ovsyannikova I, Poland G, Kennedy R . Immunosenescence and human vaccine immune responses. Immun Ageing. 2019; 16:25. PMC: 6743147. DOI: 10.1186/s12979-019-0164-9. View

4.
Rossow H, Ollgren J, Hytonen J, Rissanen H, Huitu O, Henttonen H . Incidence and seroprevalence of tularaemia in Finland, 1995 to 2013: regional epidemics with cyclic pattern. Euro Surveill. 2015; 20(33):21209. DOI: 10.2807/1560-7917.es2015.20.33.21209. View

5.
Yanes H, Hennebique A, Pelloux I, Boisset S, Bicout D, Caspar Y . Evaluation of In-House and Commercial Serological Tests for Diagnosis of Human Tularemia. J Clin Microbiol. 2017; 56(1). PMC: 5744216. DOI: 10.1128/JCM.01440-17. View